文献速递胸部肿瘤支持与姑息治疗

2009-18年中国大陆抗癌药物临床试验变化:系统综述

Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review.
PubMed 文献 · Lancet Oncol · 2019-01-01

该研究基于中国食品药品监督管理总局药物临床试验登记与信息公示平台,系统回顾2009至2018年中国大陆抗癌药物临床试验的变化。共启动1493项试验、涉及751种新测试抗癌药物,年启动试验数、新测试药物数和新增牵头临床试验单位数均随时间增加,2016年后急剧上升。实体瘤、非小细胞肺癌和淋巴瘤为最常见癌种,牵头单位地理分布不均,华东最多、西南最少。

要点

  • 2009-18年中国大陆共启动1493项抗癌药物试验,涉及751种新测试药物。
  • 年启动试验数、新测试药物数和新增牵头单位数随时间增加,2016年后急剧上升。
  • 实体瘤、非小细胞肺癌和淋巴瘤为最常见癌种,牵头单位地理分布不均。

核心结论

  • 2009至2018年中国大陆抗癌药物研发能力逐步提升,但存在癌种和地理分布不均衡的问题。

研究设计与样本

  • 基于中国食品药品监督管理总局药物临床试验登记与信息公示平台 published 的临床试验进行系统综述。
  • 共纳入1493项试验,涉及751种新测试抗癌药物。

主要发现

  • 年启动试验数、新测试药物数和新增牵头临床试验单位数随时间增加,2016年后急剧上升。
  • 在1385项可识别癌种的试验中,实体瘤325项(23%)、非小细胞肺癌232项(17%)、淋巴瘤126项(9%)为最常见。
  • 牵头单位地理分布不均,华东50家(41%)最多,西南4家(3%)最少。

临床怎么用

  • 提示政策制定者和其他利益相关方关注中国人群特有流行病学特征的肿瘤及牵头单位地理分布不均衡问题。
  • 后续研究应关注中国人群特有相关癌症、全球罕见癌症以及药物可及性公平、效率与研发可持续性之间的平衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As a result of recent, substantial capacity building, a new landscape for cancer drug trials is emerging in China. However, data on the characteristics of cancer drug trials, and how they have changed over time, are scarce. Based on clinical trials published on the China Food and Drug Administration Registration and Information Disclosure Platform for Drug Clinical Studies, we aimed to systematically review changes over time in clinical trials of cancer drugs in mainland China from 2009 to 2018, to provide insight on the effectiveness of the pharmaceutical industry and identify unmet clinical needs of stakeholders. A total of 1493 trials of 751 newly tested cancer drugs were initiated. Increases over time were observed for the annual number of initiated trials, newly tested drugs, and newly added leading clinical trial units, with a sharp increase after 2016. Of the 1385 trials in which cancer types were identified, solid tumours (325 [23%] trials), non-small-cell lung cancer (232 [17%]), and lymphoma (126 [9%]) were the most common. A markedly uneven distribution was also observed in the geography of leading units with the largest number of leading units located in east China (50 [41%]) and the smallest number located in southwest China (4 [3%]). The growth trends we observed illustrate the progress in and increasing capability of cancer drug research and development achieved in mainland China over the decade from 2009. The low number of clinical trials on tumours with epidemiological characteristics unique to the Chinese population and the unbalanced geographical distribution of leading clinical trial units will provide potential targets for policy makers and other stakeholders. Further research efforts should address cancers uniquely relevant to Chinese populations, globally rare cancers, and the balance between equitable drug access, efficiency, and sustainability of cancer drug research and development in mainland China.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Li N, Huang HY, Wu DW, et al. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review. Lancet Oncol. 2019. PMID: 31674320. doi:10.1016/S1470-2045(19)30491-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。